Foghorn Therapeutics (United States)

Foghorn is pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression. These precision therapeutic candidates target disease dependencies within the chromatin regulatory system, which means they change how genes turn on and off. Our therapies have the potential to be the next wave of medicines for cancer and other diseases.

Basic Information

Documented Facts

Evidence and Sources

Citation Guidance

Explore business profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Foghorn Therapeutics (United States).

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Foghorn is pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression. These precision therapeutic candidates target disease dependencies within the chromatin regulatory system, which means they change how genes turn on and off. Our therapies have the potential to be the next wave of medicines for cancer and other diseases.

Available profile information

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.